PE20040538A1 - Polimorfos inhibidores de xantina fosfodiesterasa v - Google Patents
Polimorfos inhibidores de xantina fosfodiesterasa vInfo
- Publication number
- PE20040538A1 PE20040538A1 PE2003000535A PE2003000535A PE20040538A1 PE 20040538 A1 PE20040538 A1 PE 20040538A1 PE 2003000535 A PE2003000535 A PE 2003000535A PE 2003000535 A PE2003000535 A PE 2003000535A PE 20040538 A1 PE20040538 A1 PE 20040538A1
- Authority
- PE
- Peru
- Prior art keywords
- degrees
- polymorph
- polymorphes
- inhibiting
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE AL POLIMORFO CRISTALINO DE 1-ETIL-3,7-DIHIDRO-8-[(1R,2R)-(HIDROXICICLOPENTIL)AMINO]-3-(2-HIDROXIETIL)-7-[(3-BROMO-4-METOXIFENIL)METIL]-1H-PURINA-2,6-DIONA EN FORMA 1 Y 2 CUYOS PATRONES DE DIFRACCION DE POLVO POR RAYOS X TIENE UBICACIONES DE PICOS CARATERISTICOS DE 7,3; 9,2; 20,2 GRADOS 2q +/- 0,5 GRADOS 2q Y DE 8,1; 11,3; 17,2 Y 22,2 GRADOS 2q +/- 0,5 GRADOS 2q RESPECTIVAMENTE. DICHO POLIMORFO SE PREPARA POR CRISTALIZACION DE DICHO POLIMORFO EN UN SOLVENTE ESENCIALMENTE NO ACUOSO ORGANICO SELECCIONADO DE ALCOHOLES, NITRILOS, ESTERES, CETONAS Y MEZCLAS DE LOS MISMOS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA RELACIONADA, QUE ES UTIL PARA TRATAR UNA VARIEDAD DE TRASTORNOS FISIOLOGICOS, TALES COMO LA DISFUNCION ERECTIL
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38448402P | 2002-05-31 | 2002-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040538A1 true PE20040538A1 (es) | 2004-08-30 |
Family
ID=29712042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000535A PE20040538A1 (es) | 2002-05-31 | 2003-05-30 | Polimorfos inhibidores de xantina fosfodiesterasa v |
Country Status (16)
Country | Link |
---|---|
US (1) | US7192962B2 (es) |
EP (1) | EP1509524B1 (es) |
JP (1) | JP2005529933A (es) |
CN (1) | CN100384844C (es) |
AR (1) | AR040233A1 (es) |
AT (1) | ATE390425T1 (es) |
AU (1) | AU2003249658A1 (es) |
CA (1) | CA2486174A1 (es) |
DE (1) | DE60319980T2 (es) |
ES (1) | ES2299720T3 (es) |
HK (1) | HK1068140A1 (es) |
MX (1) | MXPA04011865A (es) |
PE (1) | PE20040538A1 (es) |
TW (1) | TW200404802A (es) |
WO (1) | WO2003101991A1 (es) |
ZA (1) | ZA200409644B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
KR100897218B1 (ko) * | 2001-03-27 | 2009-05-14 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 결정성 이속사졸 유도체 및 그의 약학 제제 |
DK1509525T5 (da) * | 2002-05-31 | 2007-07-30 | Schering Corp | Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor |
MXPA06001195A (es) | 2003-07-31 | 2006-04-11 | Schering Corp | Metabolito de inhibidor de xantina fosfodiesterasa 5 y derivados del mismo utiles para el tratamiento de la disfuncion erectil. |
AU2004292991A1 (en) * | 2003-11-21 | 2005-06-09 | Schering Corporation | Phosphodiesterase v inhibitor formulations |
JP4880591B2 (ja) | 2004-06-04 | 2012-02-22 | テバ ファーマシューティカル インダストリーズ リミティド | イルベサルタンを含む医薬組成物 |
CN101102775A (zh) * | 2004-11-18 | 2008-01-09 | 先灵公司 | 采用pdev抑制剂治疗充血性心衰的方法 |
US20070004745A1 (en) * | 2005-03-25 | 2007-01-04 | Schering-Plough Corporation | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors |
PT1883397E (pt) * | 2005-05-17 | 2010-02-23 | Actelion Pharmaceuticals Ltd | Comprimido dispersível de bosentano |
JP2008546786A (ja) * | 2005-06-23 | 2008-12-25 | シェーリング コーポレイション | Pde5インヒビターの迅速吸収性経口処方物 |
US9012454B2 (en) | 2005-12-09 | 2015-04-21 | Mayo Foundation For Medical Education And Research | Sexual dysfunction |
WO2008139574A1 (ja) * | 2007-04-27 | 2008-11-20 | Ajinomoto Co., Inc. | ラクタム化合物の結晶形およびその製造方法 |
JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9301192D0 (en) * | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
TW403740B (en) * | 1997-06-10 | 2000-09-01 | Novartis Ag | Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
IL133357A (en) * | 1997-07-02 | 2003-12-10 | Merck & Co Inc | Polymorphic form of the tachykinin receptor antagonist 2-(r)-(1-(r)- (3,5-bis(trifluoromethyl) phenyl) ethoxy)-3-(s)-(4-fluoro) phenyl-4- (3-5(-oxo-1h, 4h-1,2,4-triazolo) methylmorpholine |
AU743515B2 (en) * | 1997-08-27 | 2002-01-24 | Elanco Tiergesundheit Ag | Dicyclanil polymorphs and hydrates and their preparation |
MA24682A1 (fr) * | 1997-10-23 | 1999-07-01 | Smithkline Beecham Corp | Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant |
FR2779726B1 (fr) * | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
DK1509525T5 (da) * | 2002-05-31 | 2007-07-30 | Schering Corp | Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor |
-
2003
- 2003-05-30 TW TW092114739A patent/TW200404802A/zh unknown
- 2003-05-30 JP JP2004509682A patent/JP2005529933A/ja active Pending
- 2003-05-30 AR ARP030101922A patent/AR040233A1/es unknown
- 2003-05-30 EP EP03756248A patent/EP1509524B1/en not_active Expired - Lifetime
- 2003-05-30 CA CA002486174A patent/CA2486174A1/en not_active Abandoned
- 2003-05-30 PE PE2003000535A patent/PE20040538A1/es not_active Application Discontinuation
- 2003-05-30 MX MXPA04011865A patent/MXPA04011865A/es active IP Right Grant
- 2003-05-30 WO PCT/US2003/016890 patent/WO2003101991A1/en active Application Filing
- 2003-05-30 AU AU2003249658A patent/AU2003249658A1/en not_active Abandoned
- 2003-05-30 ES ES03756248T patent/ES2299720T3/es not_active Expired - Lifetime
- 2003-05-30 DE DE60319980T patent/DE60319980T2/de not_active Expired - Lifetime
- 2003-05-30 US US10/449,650 patent/US7192962B2/en not_active Expired - Fee Related
- 2003-05-30 AT AT03756248T patent/ATE390425T1/de not_active IP Right Cessation
- 2003-05-30 CN CNB038124564A patent/CN100384844C/zh not_active Expired - Fee Related
-
2004
- 2004-11-29 ZA ZA200409644A patent/ZA200409644B/en unknown
-
2005
- 2005-03-03 HK HK05101861A patent/HK1068140A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2486174A1 (en) | 2003-12-11 |
EP1509524A1 (en) | 2005-03-02 |
AR040233A1 (es) | 2005-03-23 |
HK1068140A1 (en) | 2005-04-22 |
WO2003101991A1 (en) | 2003-12-11 |
ATE390425T1 (de) | 2008-04-15 |
US7192962B2 (en) | 2007-03-20 |
TW200404802A (en) | 2004-04-01 |
CN1656097A (zh) | 2005-08-17 |
ZA200409644B (en) | 2005-10-18 |
CN100384844C (zh) | 2008-04-30 |
EP1509524B1 (en) | 2008-03-26 |
AU2003249658A1 (en) | 2003-12-19 |
DE60319980T2 (de) | 2009-04-16 |
US20030232845A1 (en) | 2003-12-18 |
MXPA04011865A (es) | 2005-03-31 |
ES2299720T3 (es) | 2008-06-01 |
DE60319980D1 (en) | 2008-05-08 |
JP2005529933A (ja) | 2005-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040538A1 (es) | Polimorfos inhibidores de xantina fosfodiesterasa v | |
ES2572980T3 (es) | Combinación de inhibidores de la proteasa del VHC con un tensioactivo | |
ES2900815T3 (es) | Compuestos y métodos para inducir la condrogénesis | |
PE20061319A1 (es) | Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina | |
AR082825A2 (es) | Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios | |
BRPI0514750A (pt) | derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase | |
UY28374A1 (es) | Agentes terapéuticos | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
EA200701224A1 (ru) | Способ борьбы с грибковыми заболеваниями бобовых культур | |
AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
AR053748A1 (es) | Entidades quimicas, composiciones y metodos. | |
CO5580767A2 (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
UY28144A1 (es) | Agentes terapéuticos | |
BRPI0413232B8 (pt) | composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto | |
EA200100971A1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
AR071236A1 (es) | Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1 | |
AR068528A1 (es) | Formas solidas de n-(5-tert-butil-isoxazol-3-il)-n'-(4(7-(2-morfolin-4-il-etoxi) imidazol(2,1-b)(1,3)benzotiazol-2-il)fenil)urea, composiciones con las mismas y usos de los mismos | |
CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
PE20020566A1 (es) | DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA | |
UY27039A1 (es) | Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción | |
AR069098A1 (es) | Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c | |
DK1268418T3 (da) | Farmaceutisk aktive pyrrolidinderivater som Bax-inhibitorer | |
CL2011003302A1 (es) | Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |